In 2010 large self-insured employers paid their employees' medical claims themselves, while employees chose doctors and hospitals with little idea what a service would cost CA1. Prices for the same service varied several-fold: a colonoscopy ranged from $563 to $3,967 within one zip code CHLX-13. The negotiated prices sat with insurers, some of which treated them as trade secrets and offered their own cost estimators to members at low or no charge CHLX-13 CA1. Employers could add tools and programs to their benefits, but each one paid off only if employees found it and used it when making a medical decision CA1.
Castlight Health
Castlight sold employers price search billed on every eligible employee and lost its navigation customers to Accolade, Grand Rounds and free health plan tools, while Hinge Health, one of the programs on Castlight's own shelf, treated back and joint pain, billed for the members who used it and sold through those same benefits platforms.
Why Castlight Health lost to Hinge Health
Versus Hinge Health: Hinge Health delivered treatment for back and joint pain, counted a member only when engagement was billable, and reached employers through benefits platforms and health plans, Castlight's among them CHLX-10 CHLX-5 CHLX-2. Castlight sold price and quality search billed on every eligible employee, added engagement tools and partner programs, and sold to Vera in 2022 for about $370 million of equity value CA1 CA2 CA4. Castlight's 2020 annual report named Accolade and Grand Rounds as its most common and significant competitors, alongside health plans giving away their own care guidance tools CA3.
Arena: Market Conditions Before Castlight Health
How each step happened
Step 1 of 4 · 2010–14
Price and quality search for every service
Treatment for one condition, or prices for every service
Hinge Health chose one expensive condition and delivered the care for it. Daniel Perez and Gabriel Mecklenburg had each spent a year in rehab after injuries, and in 2014 they sketched the tools they had wanted and founded the company CHLX-14. By 2017 it ran a 12-week remote program for chronic back and knee pain, with wearable sensors guiding exercises and health coaches supporting each participant, and Perez sold it to employers as an alternative to surgery and drugs, which he said made up most of their costs CHLX-10. An employer bought a course of treatment with a start, an end and a patient whose progress could be tracked.
Castlight worked at the moment before care, when an employee picked a provider. Giovanni Colella co-founded it with Todd Park and Bryan Roberts, and its tools combined insurance claims with each employee's benefit plan to estimate out-of-pocket costs by doctor and place, alongside quality measures CHLX-12. The first customer implementation came in 2010 CA1. Among privately insured Californians the median MRI cost $746, with a range of $458 to $3,409 CHLX-12. A study of 18 employers linked use of a price-transparency tool to lower payments for selected services CA6. The savings came from employees who searched, and giving a workforce access did not mean the workforce would search CA1 CA6.
Rivals Hinge Health sold a remote program for back and joint pain, combining wearable sensors, an app and health coaching, mainly to US employers and health plans, and had 200 implementations by early 2020 CHLX-9.
Step 2 of 4 · 2014–18
Billed on eligible headcount, then bought engagement
Hinge's revenue followed participation. Its 2025 filing counted a member only when that person's engagement had been billed or was contractually billable, and it offered the vast majority of clients performance guarantees on engagement, member-reported outcomes and return on investment CHLX-5. Jim Pursley, its president, described an engagement-based model that bills for each interaction CHLX-11. Low uptake cost Hinge revenue before it cost the employer money, which gave Hinge its own reason to recruit and keep members.
Castlight priced on headcount. Its 2014 annual report said, "Our subscription fees are based on the number of employees and adult dependents that employers identify as eligible to use our offering..." CA1. Colella told the Senate Finance Committee in 2013 that engagement rates had reached as high as 80% CHLX-12, yet the invoice was the same at any level of use. Castlight answered with more engagement product. In April 2017 it completed its purchase of Jiff, issuing about 27 million shares and options, roughly 20% of the combined company CA2. In July 2018 Walmart, about 14% of revenue in 2014, said it would not renew; CEO John Doyle said it had put in place one of the five engagement fundamentals Castlight considered critical to return on investment CA1 CHLX-1.
Rivals Hinge Health had 532,326 members at the end of 2024, each counted once engagement was billable, against 15.7 million average eligible lives over the prior twelve months CHLX-5.
Step 3 of 4 · 2017–20
A shelf for other companies' programs
Hinge reached employers through platforms already sitting in their benefits stack. In December 2017 it was one of five digital health companies, Livongo among them, added to Castlight's partner ecosystem, whose programs any Castlight customer could buy with simpler contracting CHLX-2. By January 2019 Hinge listed Aon, Accolade and Castlight as strategic partners helping employers pick a chronic musculoskeletal program CHLX-3. By February 2025 its partners included all five of the largest national health plans by self-insured lives and the top three pharmacy benefit managers CHLX-5. Accolade and Castlight, two of those partners, sold navigation to the same employers Hinge wanted to reach CHLX-3 CHLX-15.
Castlight built the shelf. When the Jiff deal closed, Doyle said, "Our ability to deliver this experience in complex benefits environments with best-of-breed point solutions is unique in the market" CA2. More than 40 vendors were pre-integrated with its platform by late 2017, and Hinge's integration fed Castlight's reward points and recommendations CHLX-2 CHLX-4. Castlight coordinated other companies' care while each vendor sold its own program into the account. After Walmart, the CFO said cuts would fall hardest on sales and marketing as Castlight moved toward channel partners CHLX-1. The largest became Anthem, which licensed Castlight's navigation technology and supplied about 47% of 2020 revenue CA3.
Rivals Hinge Health had over 50 partners at the end of 2024, including health plans, pharmacy benefit managers, third-party administrators and healthcare navigation companies CHLX-5. Accolade, which Castlight's 2020 annual report named with Grand Rounds as its most common and significant competitors, went public in July 2020 at $22 a share CA3 CHLX-15.
Step 4 of 4 · 2018–22
Revenue flat, then sold to a care provider
Hinge then made each member cheaper to serve. TrueMotion, its motion-tracking software, gives real-time feedback during exercise sessions, and the company estimated that its platform cut the care-team hours of traditional physical therapy by about 95% in 2024 CHLX-5. GAAP gross margin rose from 66% in 2023 to 77% in 2024 and 80% in 2025, while revenue grew from $292.7 million to $587.9 million CHLX-5 CHLX-6. Investors valued Hinge at $6.2 billion in October 2021, and it went public in May 2025 at $32 a share CHLX-8 CHLX-7. Castlight's own partner page calls it the choice of four out of five employers that offer a digital musculoskeletal program CHLX-4.
Castlight's revenue stopped growing: $156.4 million in 2018, $143.3 million in 2019 and $146.7 million in 2020 CA3. Its 2020 annual report named Accolade and Grand Rounds as its most common and significant competitors, and said health plans such as Aetna, Cigna, Anthem and UnitedHealth offered their own care guidance tools at discounted prices or often for free CA3. Accolade had gone public in July 2020 on $132.5 million of annual revenue and was valued at about $2.5 billion by March 2021, when Grand Rounds, last valued at $1.34 billion, agreed to merge with Doctor On Demand CHLX-15 CHLX-16. Castlight added high-touch human Care Guides and in October 2019 folded Anthem's services into one SaaS agreement CA3. In January 2022 it agreed to combine with Vera Whole Health, an advanced primary care company, for $2.05 a share in cash, about $370 million of equity value CA4. Chief executive Maeve O'Meara said the deal would enable "employers to participate in full risk sharing for the first time" CA4. Vera completed the acquisition on February 17, 2022, eight years after Castlight's IPO at $16 a share CA5 CA1. Joining Vera attached Castlight's navigation to a company paid to deliver care, the position Hinge had held from its start.
Rivals Hinge Health reported $587.9 million of 2025 revenue and 782,890 members at year-end CHLX-6. Grand Rounds, which helped employees find specialists and interpret insurance claims, was last valued at $1.34 billion in 2020 before its 2021 merger with Doctor On Demand CHLX-16.
Key dates
- 2008Colella and Todd Park found the company CHLX-13
- 2010First customer implementation CA1
- 2011-11Self-insured employers pay a per-member, per-month fee; $81 million raised CHLX-13
- 2012$4.2M revenue 15 launched customers at year-end CA1
- 2013$13.0M revenue 48 launched customers at year-end CA1
- 2013-06Colella testifies to the Senate Finance Committee on price variation CHLX-12
- 2014$45.6M revenue 115 launched customers; Walmart about 14% of revenue CA1
- 2014-03IPO at $16 a share CA1
- 2017-04Jiff acquisition completed, adding engagement and rewards CA2
- 2017-07Hinge raises an $8 million Series A for a 12-week back and knee program CHLX-10
- 2017-12Hinge joins more than 40 pre-integrated partners on Castlight's platform CHLX-2
- 2018$156.4M revenue Full year CA3
- 2018-07Walmart says it will not renew CHLX-1
- 2019$143.3M revenue Full year CA3
- 2019-10Anthem's services consolidated under one SaaS agreement CA3
- 2020$146.7M revenue Anthem about 47% of revenue CA3
- 2020-07Accolade, named by Castlight as a top competitor, goes public at $22 CA3 CHLX-15
- 2021-10Hinge valued at $6.2 billion CHLX-8
- 2022-02Vera completes the acquisition at $2.05 a share CA5
- 2025-05Hinge goes public at $32 a share CHLX-7
Sources
Oldest first.
- CHLX-13 Exposing the Cost of Health Care. Trade press with executive quotes
- CHLX-12 Testimony of Dr. Giovanni Colella: High Prices, Low Transparency. Congressional testimony by the co-founder and CEO
- CA6 Association between availability of a health care price transparency tool and outpatient spending. Research analysis
- CA1 Castlight 2014 annual report. Primary filing
- CA2 Castlight completes Jiff acquisition. Primary disclosure
- CHLX-10 Hinge Health raises $8M Series A for remote monitoring of chronic pain. Trade press with CEO interview
- CHLX-2 Castlight Health Announces New Partnerships and Expanding Customer Base. Company press release with executive quotes
- CHLX-1 Castlight to restructure business after Walmart walks, laying off 50 to 75. Trade press with executive quotes
- CHLX-3 Meet Our 4 Newest Partners in Innovation. Company article
- CHLX-9 Hinge Health closes $90M Series C. Trade press with CEO interview
- CHLX-15 Benefits platform Accolade raises $220M in IPO. Trade press
- CA3 Castlight 2020 annual report. Primary filing
- CHLX-16 Grand Rounds and Doctor On Demand merge in multibillion-dollar deal. Trade press with executive interviews
- CHLX-8 Tiger, Coatue double down on Hinge Health with new $400M infusion. Trade press with CEO statement
- CA4 Castlight and Vera announce combination. Primary disclosure
- CA5 Vera completes Castlight acquisition. Primary disclosure
- CHLX-5 Hinge Health, Inc. Form S-1. Filing
- CHLX-11 Hinge Health and Cigna MSK program. Trade press with executive quotes
- CHLX-14 From cockroach award to the big board: Hinge Health's unlikely path to IPO. Trade press with founder letter quote
- CHLX-7 Hinge Health (HNGE) Prices IPO at $32 and stock flies in NYSE debut. Trade press
- CHLX-4 Hinge Health (Castlight ecosystem partner page). Company partner page
- CHLX-6 Hinge Health reports fourth quarter and full year 2025 financial results. Earnings release with CEO quote